Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma

NCT04009109 is registered in ClinicalTrials.gov with Alliance Foundation Trials, LLC. as lead sponsor.

NCT NCT04009109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04009109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
Lead sponsor
Alliance Foundation Trials, LLC.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 21, 2020
Completion date
June 30, 2027
Enrollment
79 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

myeloma, multiple